Clinical Trial Update: Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the safety, tolerability, and pharmacodynamic/pharmacokinetic profile of 7.5, 10, 12.5, or 15 mg NRL001 in a 2 g suppos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fecal Incontinence

Drugs mentioned

• NRL001

Snippet

Sponsor: Norgine | Conditions: Fecal Incontinence | Phase 1 | Status: COMPLETED